Droperidol on Prevention of Cannabis Hyperemesis Syndrome
Status unconfirmed · Phase 3
Conditions studied: Cannabis Hyperemesis Syndrome
In brief
The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.
Key facts
- Study ID
- NCT05244460
- Run by
- Mercy Health Ohio
- People needed
- 45
- Starts
- 2021-12-02
- Expected to finish
- 2023-01-31
- Last updated by the study team
- 2023-01-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- aged 18 years of age or older and presenting with cannabis hyperemesis syndrome requiring intravenous medication.
You may not qualify if…
- any patient with a contraindication to the use of droperidol
- Corrected QT interval on ECG greater than 440 milliseconds for males and greater than 450 milliseconds for females
- any prisoners
- pregnant females.
Where it is running
- Mercy Health - Austintown — Austintown, Ohio, United States (enrolling)
- St Elizabeth Boardman Hospital — Boardman, Ohio, United States (enrolling)
- St. Joseph-Warren Hospital — Warren, Ohio, United States (enrolling)
- St Elizabeth Youngstown Hospital — Youngstown, Ohio, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.